Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and... see more

TSXV:VPT - Post Discussion

View:
Post by Retiremesouth on Feb 23, 2021 8:42am

News!

Ventripoint Heart Analysis System to be used at the Stollery Children's Hospital to Study Atrial Dysfunction in Children

Tuesday, February 23, 2021, 8:40 AM ET
 

Ventripoint Heart Analysis System to be used at the Stollery Children's Hospital to Study Atrial Dysfunction in Children

February 23, 2021 -- (Ventripoint Diagnostics Ltd.) --

(TheNewswire)Toronto, Ontario TheNewswire February 23, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is announcing the commencement of a new clinical study to measure atrial volumes and ejection fractions in children with suspected valvular disease. The study is being conducted by cardiologists in the Department of Pediatrics, Division of Pediatric Cardiology at the University of Alberta in collaboration with the Mazankowski Heart Institute and Stollery Childrens Hospital.

There is a real need for a reliable, accurate and simple procedure to assess valvular function especially between the atria and ventricles of the heart. Left atrial enlargement is an indicator of diastolic dysfunction due to congenital or acquired left heart disease, volume overload due to left to right shunting, a marker of severity of mitral stenosis and regurgitation, and a risk factor for atrial arrhythmias. Right atrial volume is a known marker for right ventricular diastolic dysfunction and severity of tricuspid regurgitation or stenosis. The VMS+3.0 is uniquely able to measure volumes for all 4 chambers of the heart using 2D ultrasound and so can provide regular monitoring of children throughout their early years as the heart grows. This information is critical to determine the need and timing for therapeutic interventions.

Ventripoint is pleased to sponsor this study to further show how repeated rapid assessment paediatric patients using 2D ultrasound can assist in therapeutic decisions, stated Dr. George Adams, Executive-Chairman of Ventripoint. 3D echocardiography is often unreadable and MRI procedures are too expensive and arduous to perform frequently as the child grows.

This study aims to demonstrate the capabilities of the VMS+3.0 in assessing the performance and function of the left and right atria in combination with the ventricle assessment. For comparison purposes, the children will also be assessed by 3D ultrasound, as well as MRI, when possible.

About Stollery Childrens Hospital

The Stollery Childrens Hospital is located in Edmonton, Alberta. The hospital is comprised of 232 beds, which include inpatient and critical care beds. Over 50% of their beds are critical care beds. The Stollery Childrens Hospital provide quaternary services to Alberta and Western Canada for some of the highly specialized services. Flagship programs include the cardiac and transplant services.
Comment by ThisIsYerChance on Feb 23, 2021 8:46am
There it is. Always moving in the right direction. T.I.Y.C.
Comment by WolfOfTSXStreet on Feb 23, 2021 9:09am
Best children's hospital in the world. I believe once they test the new vms3.0 and see the ease of function, reliability, cost savings, time saving i triply believe they will order a bunch of j it's and this will kickstart vpt up and up to the moon
Comment by snuff133 on Feb 23, 2021 9:11am
Dear Friend; Attached is a news release announcing a stud of heart valve disease in children.  Here is some background: 1.      When the valve between the atrium and ventricle is defective it leads to back flow due to incomplete closure (also known as regurgitation).  This means the atrium has to work harder to push blood into the ventricle and the ventricle ...more  
Comment by invest2profit on Feb 23, 2021 9:21am
Investing in a company that is literally saving children's lives. Today's news means getting our foot in the door of another top hospital. More exposure for the VMS+3.0. Which will lead to more studies proving its effectiveness. And more hospitals following suit.
Comment by Pandora on Feb 23, 2021 10:06am
Even good news getting slammed this morning. Hopefully it will change somewhere along the way. What a sea of red!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities